Literature DB >> 30256265

Proliferative Cells From Kaposiform Lymphangiomatosis Lesions Resemble Mesenchyme Stem Cell-like Pericytes Defective in Vessel Formation.

Kathryn Glaser1, Peter Dickie1, Belinda Hsi Dickie1,2.   

Abstract

Kaposiform lymphangiomatosis (KLA) is a vascular anomaly featuring lymphatic expansion. It has no known cause, no effective treatment, and is associated with high morbidity. Proliferative cells from 3 KLA patient lesions were characterized relative to adiopose-derived mesenchyme stem cells (ADSCs) and cells derived from a patient with the related disease kaposiform hemangioendothelioma (KHE). KLA cells variably expressed markers of mesenchyme stem cells (CD73, CD90, CD105, CD146) and lacked endothelial cell markers (CD31, CD34) as determined by flow cytometry. They expressed markers of vascular pericytes (neural/glial antigen 2, alpha-smooth muscle actin, platelet-derived growth factor-beta receptor, and CXCL12) as determined by quantitative reverse transcription polymerase chain reaction. Lesion cells transcribed vascular markers VEGFC and VEGFD, as well as VCAM-1, the latter of which was confirmed by flow cytometry, consistent with angiogenic MSC-like pericytes. Furthermore, conditioned medium from each was shown to promote the proliferation of growth factor-starved lymphatic endothelial cells. Unlike kaposiform hemangioendothelioma-derived MSC-like pericytes and ADSCs, KLA isolates were defective in support of vascular network formation in co-cultures with either vascular or lymphatic endothelial cells. Genetic analysis by whole exome sequencing revealed novel variant alleles in 2 populations of KLA cells (BAD, TSC1) that may bear on aberrant pericyte growth and function.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30256265     DOI: 10.1097/MPH.0000000000001284

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  7 in total

1.  Signaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosis.

Authors:  Elisa Boscolo; Patricia Pastura; Kathryn Glaser; Jillian Goines; Adrienne M Hammill; Denise M Adams; Peter Dickie; Belinda Hsi Dickie; Timothy D Le Cras
Journal:  Pediatr Blood Cancer       Date:  2019-05-02       Impact factor: 3.167

2.  Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition.

Authors:  Guy Chowers; Gadi Abebe-Campino; Hana Golan; Asaf Vivante; Shoshana Greenberger; Michalle Soudack; Galia Barkai; Ilana Fox-Fisher; Dong Li; Michael March; Mark R Battig; Hakon Hakonarson; Denise Adams; Yoav Dori; Adi Dagan
Journal:  Pediatr Res       Date:  2022-03-04       Impact factor: 3.953

3.  Kaposiform lymphangiomatosis and kaposiform hemangioendothelioma: similarities and differences.

Authors:  Yi Ji; Siyuan Chen; Suhua Peng; Chunchao Xia; Li Li
Journal:  Orphanet J Rare Dis       Date:  2019-07-05       Impact factor: 4.123

Review 4.  Kaposiform hemangioendothelioma: current knowledge and future perspectives.

Authors:  Yi Ji; Siyuan Chen; Kaiying Yang; Chunchao Xia; Li Li
Journal:  Orphanet J Rare Dis       Date:  2020-02-03       Impact factor: 4.123

5.  Chronic lymphedema in patients with kaposiform hemangioendothelioma: incidence, clinical features, risk factors and management.

Authors:  Yi Ji; Siyuan Chen; Chuncao Xia; Jiangyuan Zhou; Xian Jiang; Xuewen Xu; Kaiying Yang; Xuepeng Zhang; Feiteng Kong; Guoyan Lu; Yongbo Zhang
Journal:  Orphanet J Rare Dis       Date:  2020-11-07       Impact factor: 4.123

6.  Identification of distinct tumor cell populations and key genetic mechanisms through single cell sequencing in hepatoblastoma.

Authors:  Alexander Bondoc; Kathryn Glaser; Kang Jin; Charissa Lake; Stefano Cairo; James Geller; Gregory Tiao; Bruce Aronow
Journal:  Commun Biol       Date:  2021-09-08

Review 7.  Osteopathy in Complex Lymphatic Anomalies.

Authors:  Ernesto Solorzano; Andrew L Alejo; Hope C Ball; Joseph Magoline; Yusuf Khalil; Michael Kelly; Fayez F Safadi
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.